title: A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells.
abstract: Androgen deprivation therapy in prostate cancer (PCa) causes neuroendocrine differentiation (NED) of prostatic adenocarcinomas (PAC) cells, leading to recurrence of PCa. Androgen-responsive genes involved in PCa progression including NED remain largely unknown. Here we demonstrated the importance of androgen receptor (AR)-microRNA-204 (miR-204)-XRN1 axis in PCa cell lines and the rat ventral prostate. Androgens downregulate miR-204, resulting in induction of XRN1 (5'-3' exoribonuclease 1), which we identified as a miR-204 target. miR-204 acts as a tumor suppressor in two PAC cell lines (LNCaP and 22Rv1) and as an oncomiR in two neuroendocrine-like prostate cancer (NEPC) cell lines (PC-3 and CL1). Importantly, overexpression of miR-204 and knockdown of XRN1 inhibited AR expression in PCa cells. Repression of miR-34a, a known AR-targeting miRNA, contributes AR expression by XRN1. Thus we revealed the AR-miR-204-XRN1-miR-34a positive feedback loop and a dual function of miR-204/XRN1 axis in prostate cancer.
authors: State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.|WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Miao
authors: M
authors: Ding
authors: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.|Department of Urology, University of Washington, Seattle, WA, USA.
authors: Biaoyang
authors: B
authors: Lin
authors: Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
authors: Tao
authors: T
authors: Li
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Yuanyuan
authors: Y
authors: Liu
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Yuhua
authors: Y
authors: Li
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Xiaoyu
authors: X
authors: Zhou
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Maohua
authors: M
authors: Miao
authors: State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
authors: Jinfa
authors: J
authors: Gu
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Hongjie
authors: H
authors: Pan
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Fen
authors: F
authors: Yang
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
authors: Tianqi
authors: T
authors: Li
authors: State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
authors: Xin Yuan
authors: XY
authors: Liu
authors: WHO Collaborating Center for Research in Human Reproduction, Shanghai, China.|Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.|The Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.|Institute of Reproduction and Development, Fudan University, Shanghai, China.
authors: Runsheng
authors: R
authors: Li
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D002369:Castration; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D015536:Down-Regulation; D005095:Exoribonucleases / Q000235:genetics* / Q000378:metabolism; D064593:Heterografts; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D014162:Transfection
chemical_list: C549404:MIRN204 microRNA, human; D035683:MicroRNAs; D008869:Microtubule-Associated Proteins; D005095:Exoribonucleases; C470512:XRN1 protein, human
keywords: XRN1; miR-204; prostate cancer